Pfizer and Roche release positive study results with InSphero

http://www.insphero.chImportant key customers of InSphero AG, market leader in the area of three dimensional cell culture models for pharmaceutical research, presented the advantages of InSphero’s 3D-InSight-Micro tissues at international congresses.The 3D-micro tissues developed by InSphero build up human organs true to original in a miniaturized scale, enabling the improvement of predictability of in vitro tests analyzing new drug compounds.

Recently, the leading US pharma company Pfizer could show that the InSphero 3D-InSight liver tissues, which contain all important cell types of the human liver, delivered unmatched results in studies investigating the effects of liver toxic substances. These positive results were presented at the world’s most renowned toxicology congress (Annual SOT Meeting, San Antonio).
Further positive results were presented by Roche at the annual congress of the American Association of Cancer Research in Washington DC. The organotypical structure of InSphero’s 3D-micro tissues for the first time allowed reconstructing the mechanism of action of a complex antibody-based cancer drug. This technology enables the optimization of substances in vitro, thereby reducing extent and risk of following clinical tests.

“These positive study results emphasize the successful application of our technology in drug development. In the meantime InSphero is working together with all top-10 pharma companies and will for certain be able to present further exciting results within the next months”, states Dr. Jan Lichtenberg, CEO and Cofounder of InSphero. Accordingly it is not surprising that Nature – one of the world’s most prestigious scientific journals – has recently published an extensive report about InSphero and the successful introduction of the 3D technology into the pharmaceutical industry.

This entry was posted in Portfolio, Redalpine Capital I and tagged , , .
Bookmark the permalink. Follow any comments here with the RSS feed for this post.
Comments are closed, but you can leave a trackback: Trackback URL.